No link to cardiac valvulopathy was seen in cabergoline treated patients
<p><strong>Objective:</strong> To evaluate the association between use of cabergoline in patients with prolactinoma and risk of developing clinically relevant cardiac valvular disease.</p> <p><strong>Method:</strong> This was a descriptive cross sectional st...
Auteurs principaux: | K Dharshini, Noel Somasundaram, HMDPK Senevirathna, S Raj Kumar |
---|---|
Format: | Article |
Langue: | English |
Publié: |
Sri Lanka College of Endocrinologists
2012-10-01
|
Collection: | Sri Lanka Journal of Diabetes Endocrinology and Metabolism |
Sujets: | |
Accès en ligne: | https://sjdem.sljol.info/articles/4775 |
Documents similaires
-
Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma
par: Shruti Khare, et autres
Publié: (2017-01-01) -
Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma
par: Annabelle G Hayes, et autres
Publié: (2023-01-01) -
Early Prediction of Long-Term Response to Cabergoline in Patients with Macroprolactinomas
par: Youngki Lee, et autres
Publié: (2014-09-01) -
Spontaneous reduction of prolactinoma post cabergoline withdrawal
par: Sampath Kumar Venkatesh, et autres
Publié: (2012-01-01) -
The course of pregnancy and delivery in patients with prolactinoma during treatment with cabergoline
par: Larisa Dzeranova, et autres
Publié: (2016-11-01)